Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncology Pharma Inc ONPH

Healthcare Biotechnology
Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals... see more

Recent & Breaking News (GREY:ONPH)

Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

Accesswire July 12, 2022

Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

Accesswire June 29, 2022

Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development

Accesswire June 8, 2022

Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development

Accesswire May 9, 2022

Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer

Accesswire April 13, 2022

Oncology Pharma Reports on Progress with Ribera Solutions

Accesswire March 2, 2022

Oncology Pharma Releases Further Feasibility Studies, Data and Capacities

Accesswire February 23, 2022

Oncology Pharma Expands on Feasibility Studies and Data

Accesswire February 17, 2022

Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine

Accesswire February 14, 2022

Oncology Pharma Gives Update on Technology, Formulation and Data Creation

Accesswire February 8, 2022

Oncology Pharma's New Year Update

Accesswire January 10, 2022

Oncology Pharma Meeting Towards Future Developments

Accesswire December 17, 2021

Oncology Pharma Year End Review and Outlook

Accesswire December 9, 2021

Oncology Pharma Research and Vision

Accesswire November 30, 2021

Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate

Accesswire November 8, 2021

Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress

Accesswire October 27, 2021

Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing

Accesswire October 15, 2021

Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement

Accesswire October 12, 2021

Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product

Accesswire September 13, 2021

Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives

Accesswire August 23, 2021